ADA Scientific Sessions 2026 Abstract

Zenagamtide (Amycretin), a Novel Unimolecular GLP-1 and Amylin Receptor Agonist: Phase 2b Results in T2D

By Pablo F. Mora, Vanita Aroda, Marisse Asong, Julio Rosenstock

Trial in peopleInterventions

The paper

Pablo F. Mora, Vanita Aroda, Marisse Asong, Julio Rosenstock

Dallas

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1730-P

doi.org/10.2337/db26-1730-p

The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety